ROSTOR

This brand name is authorized in Nigeria. It is also authorized in Australia, South Africa.

Active ingredients

The drug ROSTOR contains one active pharmaceutical ingredient (API):

1	Rosuvastatin UNII 83MVU38M7Q - ROSUVASTATIN CALCIUM
	Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.
	Read more about Rosuvastatin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-3179	Tablet	Rostor 10 Tablet TAB 10 mg 3 x 10's (in Alu-Alu blisters)	Film Coated Tablet A yellow colored, round shaped, biconvex film coated tablets	28/01/2021
B4-3317	Tablet	Rostor 20 Tablets TAB 20 mg 3 x 10's	Tablet	07/05/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AA07	Rosuvastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2574L, 2584B, 2590H, 2594M, 2606E, 2609H, 2628H, 2636R
NG	Registered Drug Product Database	B4-3179, B4-3317
ZA	Health Products Regulatory Authority	46/7.5/0222, 46/7.5/0223, 46/7.5/0224, 46/7.5/0225